To include your compound in the COVID-19 Resource Center, submit it here.

Tibotec, Gilead to develop HIV combinations

Tibotec Pharmaceuticals and Gilead Sciences Inc. (NASDAQ:GILD) agreed to develop and commercialize a fixed-dose HIV treatment combining Tibotec's marketed Prezista darunavir and Gilead's investigational

Read the full 246 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE